Encochleated amphotericin B - Matinas BioPharma

Drug Profile

Encochleated amphotericin B - Matinas BioPharma

Alternative Names: CAmB; MAT 2203

Latest Information Update: 24 Apr 2017

Price : $50

At a glance

  • Originator Aquarius Biotechnologies
  • Developer Aquarius Biotechnologies; Matinas BioPharma
  • Class Antifungals; Antiprotozoals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Candidiasis; Mycoses; Vulvovaginal candidiasis
  • Preclinical Aspergillosis; Cryptococcosis; Visceral leishmaniasis

Most Recent Events

  • 03 Apr 2017 Matinas BioPharma initiates a phase IIa extension trial for Candidiasis (chronic mucocutaneous)
  • 06 Mar 2017 Matinas BioPharma plans a phase IIa extension trial for Candidiasis
  • 06 Mar 2017 The Institutional Review Board of the National Institute of Allergy and Infectious Diseases (NIAID) approves IND application for Phase IIa extension trial in Candidiasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top